<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-048814</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Topiramate in comorbid disorders: epilepsy and migraine</dc:title>
<dc:description xml:lang="en">Introduction. With relative frequency epilepsy and migraine are associated in a same patient. Some times it isdifficult to distinguish an attack of others. Reason why it would be of utility to have a treatment effective in both pathologies.It is tried to study in patients with this comorbidity, how of effective it is a drug indicated in the two pathologies, as it istopiramate. Patients and methods. An observational, longitudinal and prospective study is made, where 15 patients arerecruited with this association, and which they were treated with topiramate. They are revaluated at three and six months oftreatment. Results. Significant differences are obtained (p &lt; 0.05) in all the studied variables (severity and duration of themigraine attacks and frequency of the migraine and epileptic attacks), with a medium dose of 100 mg/day of topiramate, at theend of the study. Not serious adverse effects were observed. Conclusions. Topiramate in monotherapy seems to be a suitabletreatment in patients who undergo epileptic and migrainous attacks jointly</dc:description>
<dc:creator>Anciones, B</dc:creator>
<dc:creator>Sepúlveda-Sánchez, J. M</dc:creator>
<dc:creator>Gilo-Arrojo, F</dc:creator>
<dc:creator>Gómez-Argüelles, J. M</dc:creator>
<dc:creator>Herrera, A</dc:creator>
<dc:creator>Aragón, E</dc:creator>
<dc:creator>Dorado, R</dc:creator>
<dc:creator>González de la Aleja, J</dc:creator>
<dc:creator>Blanco, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción. Con relativa frecuencia la epilepsia y lamigraña se ven asociadas en un mismo paciente. Algunas veces esdifícil distinguir unas crisis de otras. Por tanto, sería de utilidadposeer un tratamiento que fuera eficaz en ambas patologías. Sepretende estudiar la eficacia del topiramato en el tratamiento delos pacientes que padecen epilepsia y migraña. Pacientes y métodos.Se realiza un estudio observacional, longitudinal y prospectivo,donde se recoge la frecuencia de las crisis, tanto de migrañacomo epilépticas, en una serie de 15 pacientes con dicha comorbilidad,tratados con topiramato. Se reevalúan a los tres y seis mesesde tratamiento. Resultados. Se obtienen diferencias significativas(p &lt; 0,05) en todas las variables estudiadas (intensidad y duraciónde las crisis migrañosas y frecuencia de crisis migrañosas y epilépticas),con una dosis mediana de topiramato de 100 mg/día al finalizarel estudio. No se observaron efectos adversos graves. Conclusiones.El topiramato en monoterapia parece ser un tratamientoefectivo en pacientes que sufren conjuntamente crisis epilépticas ymigrañosas</dc:description>
<dc:source>Rev Neurol;43(4): 193-196, ago. 2006. tab, graf</dc:source>
<dc:identifier>ibc-048814</dc:identifier>
<dc:title xml:lang="es">Topiramato en enfermedades comórbidas: epilepsia y migraña</dc:title>
<dc:subject>^d29623</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d5768^s22003</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d934^s22073</dc:subject>
<dc:subject>^d4907^s22032</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d28630</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d4907^s22057</dc:subject>
<dc:subject>^d24572</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d32116^s22073</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d9068^s22032</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d9068^s22057</dc:subject>
<dc:subject>^d5768^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200608</dc:date>
</metadata>
</record>
</ibecs-document>
